PLRX vs GILD vs IDYA

For growth investors, IDEAYA Biosciences, Inc.

(IDYA) is the stronger pick with 30. 2% revenue growth year-over-year, versus 2. 4% for Gilead Sciences, Inc. (GILD). Gilead Sciences, Inc. (GILD) offers the better valuation at 18. 5x trailing P/E, making it the more compelling value choice. Analysts rate Gilead Sciences, Inc. (GILD) a "Buy" — based on 58 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +106. 5%, compared to -96. 6% for Pliant Therapeutics, Inc. (PLRX). Over 10 years, the gap is even starker: IDYA returned +159. 0% versus PLRX's -94. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Gilead Sciences, Inc.

(GILD) is the lower-risk stock at 0. 54β versus IDEAYA Biosciences, Inc. 's 1. 25β — meaning IDYA is approximately 130% more volatile than GILD relative to the S&P 500. On balance sheet safety, IDEAYA Biosciences, Inc. (IDYA) carries a lower debt/equity ratio of 3% versus 109% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEAYA Biosciences, Inc.

(IDYA) is pulling ahead at 30. 2% versus 2. 4% for Gilead Sciences, Inc. (GILD). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to 30. 0% for Pliant Therapeutics, Inc.. Over a 3-year CAGR, IDYA leads at 62. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus -52. 0% for IDEAYA Biosciences, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 39. 7% versus -72. 8% for IDYA. At the gross margin level — before operating expenses — IDYA leads at 97. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, GILD (2.

5% yield) pays a dividend. PLRX, IDYA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Gilead Sciences, Inc.

(GILD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 2. 5% yield). Both have compounded well over 10 years (GILD: +81. 5%, PLRX: -94. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PLRX is a small-cap quality compounder stock; GILD is a mid-cap quality compounder stock; IDYA is a small-cap high-growth stock. GILD pays a dividend while PLRX, IDYA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.